itch – Prof. Marcus Maurer

Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies

164.

Kühn, H., Kolkhir, P., Babina, M., Düll, M., Frischbutter, S., Fok, J. S., Jiao, Q., Metz, M., Scheffel, J., Wolf, K., Kremer, A. E., and Maurer, M.⁺: Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies. J. Allergy Clin. Immunol. 2021: 147; 456-469. IF: 14.29

r.164

Flare size but not intensity reflects histamine-induced itch

admin

406.	Lehmann, S., Deuring, E., Weller, K., Scheffel, J., Metz, M., Maurer, M., and Hawro, T.⁺: Flare size but not intensity reflects histamine-induced itch. Skin Pharmacol. Phys. 2020: 33; 244-252. IF: 3.48

o.406

Flare size but not intensity reflects histamine-induced itch Read More »

Urticaria

mm-red

32.	Maurer, M., Magerl, M., Zuberbier, T., and Weller, K.: Urticaria. In: Kabashima, K., editor: Immunology of the skin. Japan: Springer, 2016

Urticaria Read More »

Anti-pruritic effect of sertaconazole 2% cream in atopic dermatitis subjects: a prospective, randomized, double-blind, vehicle-controlled, multi-centre clinical trial of efficacy, safety and local tolerability

mm-red

248

Ständer, S.+, Metz, M., Ramos, M. H., Maurer, M. Schoepke, N., Tsianakas, A., Zeidler, C., and Luger, T. A.: Anti-pruritic effect of sertaconazole 2% cream in atopic dermatitis subjects: a prospective, randomized, double-blind, vehicle-controlled, multi-centre clinical trial of efficacy, safety and local tolerability. Acta Derm. Venereol. 2016: 96; 792-796. IF: 3.65

Anti-pruritic effect of sertaconazole 2% cream in atopic dermatitis subjects: a prospective, randomized, double-blind, vehicle-controlled, multi-centre clinical trial of efficacy, safety and local tolerability Read More »

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy

mm-red

211

Casale, T. B., Bernstein, J. A., Maurer, M. Saini, S. S., Trzaskoma, B., Chen, H., Grattan, C., Gimenèz-Arnau, A., Kaplan, A. P., and Rosén, K.+: Similar efficacy with Omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J. Allergy Clin. Immunol. Pract. 2015: 3; 743-750. IF: 5.42

The German version of ItchyQoL: validation and initial clinical findings

mm-red

168	Krause, K., Kessler, B., Weller, K., Veidt, J., Chen, S. C., Martus, P., Church, M. K., Metz, M., and Maurer, M.+: The German version of ItchyQoL: validation and initial clinical findings. Acta Derm. Venereol. 2013: 93; 562-568. IF: 4.24

o.168

The German version of ItchyQoL: validation and initial clinical findings Read More »

Effective control of recalcitrant pruritus by bevacizumab – a possible role for VEGF in chronic itch?

mm-red

164	Krause, K., Krull, C., Keßler, B., Lange-Asschenfeldt, B., Maurer, M. and Metz, M.+: Effective control of recalcitrant pruritus by bevacizumab – a possible role for VEGF in chronic itch? Acta Derm. Venereol. 2013: 2; 175-179. IF: 4.24

Effective control of recalcitrant pruritus by bevacizumab – a possible role for VEGF in chronic itch? Read More »

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

mm-red

163

Kaplan, A., Ledford, D., Ashby, M., Canvin, J, Zazzali, J. L., Conner, E., Veith, J., Kamath, N., Staubach, P., Jakob, T., Stirling, R. G., Kuna, P., Berger, W., Maurer, M. and Rosén, K.+: Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J. Allergy Clin. Immunol. 2013: 132; 101-109. IF: 11.25

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Read More »